With unrelenting drive, Janssen Oncology is applying the most compelling science to bring forward transformational solutions to intercept and cure cancer.

Our Discovery groups are part of integrated teams that also include early and late development, and commercialization. Each of these integrated teams is focused on a specific disease area. This allows Discovery scientists to work closely with development and commercialization experts and fully leverage advanced research platforms against clearly defined medical needs, therapeutic pathways and targets.

Our Cutting-edge Research Platforms

Small molecules – Targeted therapies such as those that inhibit specific processes necessary for tumor proliferation or migration.

T cell redirection – Recombinant proteins bridge T cells and tumor cells, redirecting T cells to better target tumors.

Antibodies – Monoclonal antibodies are identical immunoglobulins generated from a single B cell clone. These antibodies recognize binding sights on a single antigen, such as CD38, a surface protein that is highly expressed across multiple myeloma cells. Bispecific antibodies target antigens and T cells; bi- and tri-specifics target multiple antigens.

Chimeric antigen receptor-T cell (CAR-T) therapy – T cells from patients or healthy donors are genetically engineered to include these receptors, which specifically direct the T cells to recognize and kill cancer cells.

Oncolytic viruses – Enable the simultaneous delivery of multiple immune-modulating agents.

Vaccines – Trigger T cell responses against cancer cells.